First In-Human Medical Imaging with a PASylated 89Zr-LabeledAnti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer
10.1007/s13139-020-00638-7
- Author:
Antonia RICHTER
1
;
Karina KNORR
;
Martin SCHLAPSCHY
;
Stephanie ROBU
;
Volker MORATH
;
Claudia MENDLER
;
Hsi-Yu YEN
;
Katja STEIGER
;
Marion KIECHLE
;
Wolfgang WEBER
;
Arne SKERRA
;
Markus SCHWAIGER
Author Information
1. Nuklearmedizinische Klinik und Poliklinik, Klinikumrechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675 Munich, Germany
- Publication Type:ORIGINAL ARTICLE
- From:Nuclear Medicine and Molecular Imaging
2020;54(2):114-119
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecularimaging. Here we report the first clinical translation of a PASylated Fab fragment (89Zr∙Df-HER2-Fab-PAS200) for the molecularimaging of tumor-related HER2 expression.
Methods:A patient with HER2-positive metastatic breast cancer received 37 MBq of 89Zr∙Df-HER2-Fab-PAS200 at a total massdose of 70 μg. PET/CT was carried out 6, 24, and 45 h after injection, followed by image analysis of biodistribution, normalorgan uptake, and lesion targeting.
Results:Images show a biodistribution typical for protein tracers, characterized by a prominent blood pool 6 h p.i., whichdecreased over time. Lesions were detectable as early as 24 h p.i. 89Zr∙Df-HER2-Fab-PAS200 was tolerated well.
Conclusion:This study demonstrates that a PASylated Fab tracer shows appropriate blood clearance to allow sensitive visualizationof small tumor lesions in a clinical setting.
